Atlas Venture is a leading early-stage venture capital firm that invests in technology and life sciences companies. Since inception in 1980, its partners have helped build over 350 companies in more than 16 different countries. The firm is currently investing in its eighth fund and manages over $2 billion in committed capital.
For more information visit www.atlasventure.com
Established in 1996, the Novartis Venture Fund currently manages over over $750m in committed capital and has invested globally in ore than 50 private life sciences companies across therapeutics, vaccines, devices and diagnostics. As a financially driven corporate life science investor, the Novartis Venture Fund invests in those companies which have the potential to lead the next innovation wave in new areas that will be critical to patient care. The Novartis Venture Fund team of eight investment professionals based in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in drug development, medical devices, and venture capital.
For more information, visit www.venturefund.novartis.com
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
For more information visit www.srone.com
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
For more information visit www.svlsa.com